{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:48:56Z","timestamp":1794311336253,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","award":["16242"],"award-info":[{"award-number":["16242"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","award":["16242"],"award-info":[{"award-number":["16242"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","award":["16242"],"award-info":[{"award-number":["16242"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","award":["16242"],"award-info":[{"award-number":["16242"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Michael J. Fox Foundation for Parkinson&apos;s Research"},{"name":"Michael J. Fox Foundation for Parkinson&apos;s Research"},{"name":"Michael J. Fox Foundation for Parkinson&apos;s Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The development of high efficiency, central nervous system (CNS) targeting AAV-based gene therapies is necessary to address challenges in both pre-clinical and clinical investigations. The engineered capsids, AAV.PHP.B and AAV.PHP.eB, show vastly improved blood-brain barrier penetration compared to their parent serotype, AAV9, but with variable effect depending on animal system, strain, and delivery route. As most characterizations of AAV.PHP variants have been performed in mice, it is currently unknown whether AAV.PHP variants improve CNS targeting when delivered intrathecally in rats. We evaluated the comparative transduction efficiencies of equititer doses (6\u2009\u00d7\u200910\n                    <jats:sup>11<\/jats:sup>\n                    vg) of AAV.PHP.eB-CAG-GFP and AAV9-CAG-GFP when delivered into the cisterna magna of 6\u20139-month old rats. Using both quantitative and qualitative assessments, we observed consistently superior biodistribution of GFP+ cells and fibers in animals treated with AAV.PHP.eB compared to those treated with AAV9. Enhanced GFP signal was uniformly observed throughout rostrocaudal brain regions in AAV.PHP.eB-treated animals with matching GFP protein expression detected in the forebrain, midbrain, and cerebellum. Collectively, these data illustrate the benefit of intracisternal infusions of AAV.PHP.eB as an optimal system to distribute CNS gene therapies in preclinical investigations of rats, and may have important translational implications for the clinical CNS targeting.\n                  <\/jats:p>","DOI":"10.1038\/s41434-021-00244-y","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T03:03:09Z","timestamp":1616382189000},"page":"390-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9"],"prefix":"10.1038","volume":"29","author":[{"given":"Diptaman","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4575-2380","authenticated-orcid":false,"given":"David J.","family":"Marmion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi L.","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric P.","family":"Manfredsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0407-1861","authenticated-orcid":false,"given":"Jeffrey H.","family":"Kordower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"244_CR1","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20:1172\u20139.","journal-title":"Nat Neurosci"},{"key":"244_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016;34:204\u20139.","journal-title":"Nat Biotechnol"},{"key":"244_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","volume":"26","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The neurotropic properties of AAV-PHP.B are limited to C57BL\/6\u2009J Mice. Mol Ther. 2018;26:664\u20138.","journal-title":"Mol Ther"},{"key":"244_CR4","first-page":"116","volume":"9","author":"KL Jackson","year":"2016","unstructured":"Jackson KL, Dayton RD, Deverman BE, Klein RL. Better targeting, better efficiency for wide-scale neuronal transduction with the synapsin promoter and AAV-PHP.B. Front Mol Neurosci. 2016;9:116.","journal-title":"Front Mol Neurosci"},{"key":"244_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41434-018-0028-5","volume":"25","author":"RD Dayton","year":"2018","unstructured":"Dayton RD, Grames MS, Klein RL. More expansive gene transfer to the rat CNS: AAV PHP.EB vector dose-response and comparison to AAV PHP.B. Gene Ther. 2018;25:392\u2013400.","journal-title":"Gene Ther"},{"key":"244_CR6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","volume":"27","author":"WA Liguore","year":"2019","unstructured":"Liguore WA, Domire JS, Button D, Wang Y, Dufour BD, Srinivasan S, et al. AAV-PHP.B administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice. Mol Ther. 2019;27:2018\u201337.","journal-title":"Mol Ther"},{"key":"244_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","volume":"9","author":"RM Bailey","year":"2018","unstructured":"Bailey RM, Armao D, Nagabhushan Kalburgi S, Gray SJ. Development of intrathecal AAV9 gene therapy for giant axonal neuropathy. Mol Ther Methods Clin Dev. 2018;9:160\u201371.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"244_CR8","doi-asserted-by":"publisher","first-page":"146832","DOI":"10.1016\/j.brainres.2020.146832","volume":"1739","author":"RM Bailey","year":"2020","unstructured":"Bailey RM, Rozenberg A, Gray SJ. Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies. Brain Res. 2020;1739:146832.","journal-title":"Brain Res"},{"key":"244_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/gt.2017.18","volume":"24","author":"K Bey","year":"2017","unstructured":"Bey K, Ciron C, Dubreil L, Deniaud J, Ledevin M, Cristini J, et al. Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders. Gene Ther. 2017;24:325\u201332.","journal-title":"Gene Ther"},{"key":"244_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2012.101","volume":"20","author":"SJ Gray","year":"2013","unstructured":"Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude, Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013;20:450\u20139.","journal-title":"Gene Ther"},{"key":"244_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/JPD-191590","volume":"9","author":"D Chatterjee","year":"2019","unstructured":"Chatterjee D, Sanchez DS, Quansah E, Rey NL, George S, Becker K, et al. Loss of one Engrailed1 allele enhances induced alpha-synucleinopathy. J Parkinsons Dis. 2019;9:315\u201326.","journal-title":"J Parkinsons Dis"},{"key":"244_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J, Zhang B, O\u2019Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949\u201353.","journal-title":"Science"},{"key":"244_CR13","doi-asserted-by":"publisher","first-page":"27053","DOI":"10.1073\/pnas.1910061116","volume":"116","author":"M Davidsson","year":"2019","unstructured":"Davidsson M, Wang G, Aldrin-Kirk P, Cardoso T, Nolbrant S, Hartnor M, et al. A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism. Proc Natl Acad Sci USA 2019;116:27053\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"244_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41592-020-0799-7","volume":"17","author":"S Ravindra Kumar","year":"2020","unstructured":"Ravindra Kumar S, Miles TF, Chen X, Brown D, Dobreva T, Huang Q, et al. Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types. Nat Methods. 2020;17:541\u201350.","journal-title":"Nat Methods"},{"key":"244_CR15","doi-asserted-by":"publisher","first-page":"eaau9859","DOI":"10.1126\/sciadv.aau9859","volume":"4","author":"MJ Castle","year":"2018","unstructured":"Castle MJ, Cheng Y, Asokan A, Tuszynski MH. Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion. Sci Adv. 2018;4:eaau9859.","journal-title":"Sci Adv"},{"key":"244_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.omtm.2020.10.011","volume":"19","author":"SN Mathiesen","year":"2020","unstructured":"Mathiesen SN, Lock JL, Schoderboeck L, Abraham WC, Hughes SM. CNS transduction benefits of AAV-PHP.eB over AAV9 are dependent on administration route and mouse strain. Mol Ther Methods Clin Dev. 2020;19:447\u201358.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"244_CR17","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1172\/JCI121658","volume":"128","author":"CJ Sumner","year":"2018","unstructured":"Sumner CJ, Crawford TO. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest. 2018;128:3219\u201327.","journal-title":"J Clin Invest"},{"key":"244_CR18","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/brain\/awaa254","volume":"143","author":"B Lutters","year":"2020","unstructured":"Lutters B, Koehler PJ. A road less travelled: the centenary of cisterna magna puncture. Brain. 2020;143:2858\u201362.","journal-title":"Brain"},{"key":"244_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuron.2019.03.020","volume":"102","author":"E Hudry","year":"2019","unstructured":"Hudry E, Vandenberghe LH, Therapeutic AAV. Gene transfer to the nervous system: a clinical reality. Neuron. 2019;102:263.","journal-title":"Neuron"},{"key":"244_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27:59\u201365.","journal-title":"Nat Biotechnol"},{"key":"244_CR21","doi-asserted-by":"publisher","first-page":"15036","DOI":"10.1038\/mtm.2015.36","volume":"2","author":"KL Jackson","year":"2015","unstructured":"Jackson KL, Dayton RD, Klein RL. AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats. Mol Ther Methods Clin Dev. 2015;2:15036.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"244_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29:285\u201398.","journal-title":"Hum Gene Ther"},{"key":"244_CR23","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ymthe.2019.02.013","volume":"27","author":"J Hordeaux","year":"2019","unstructured":"Hordeaux J, Yuan Y, Clark PM, Wang Q, Martino RA, Sims JJ, et al. The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol Ther. 2019;27:912\u201321.","journal-title":"Mol Ther"},{"key":"244_CR24","doi-asserted-by":"publisher","first-page":"e0225206","DOI":"10.1371\/journal.pone.0225206","volume":"14","author":"Q Huang","year":"2019","unstructured":"Huang Q, Chan KY, Tobey IG, Chan YA, Poterba T, Boutros CL, et al. Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids. PLoS One. 2019;14:e0225206.","journal-title":"PLoS One"},{"key":"244_CR25","doi-asserted-by":"publisher","first-page":"7326","DOI":"10.1128\/JVI.00448-12","volume":"86","author":"CL Bell","year":"2012","unstructured":"Bell CL, Gurda BL, Van Vliet K, Agbandje-McKenna M, Wilson JM. Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J Virol. 2012;86:7326\u201333.","journal-title":"J Virol"},{"key":"244_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/mt.2016.49","volume":"24","author":"C Summerford","year":"2016","unstructured":"Summerford C, Johnson JS, Samulski RJ. AAVR: a multi-serotype receptor for AAV. Mol Ther. 2016;24:663\u20136.","journal-title":"Mol Ther"},{"key":"244_CR27","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ymthe.2020.03.007","volume":"28","author":"SK Powell","year":"2020","unstructured":"Powell SK, Samulski RJ, McCown TJ. AAV capsid-promoter interactions determine CNS cell-selective gene expression in vivo. Mol Ther. 2020;28:1373\u201380.","journal-title":"Mol Ther"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00244-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00244-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00244-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T19:02:58Z","timestamp":1655406178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00244-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["244"],"URL":"https:\/\/doi.org\/10.1038\/s41434-021-00244-y","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}